{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-070107","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.680865+00:00","generated_at":"2026-06-14T02:49:29.461475+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Ocular Therapeutix reports positive 12-month Phase 1 data for OTX-TKI in wet AMD","bullets":["12-month data showed OTX-TKI maintained controlled wet AMD comparable to aflibercept, with mean BCVA change of -1.0 letters vs +2.0 letters.","89% reduction in treatment burden observed in OTX-TKI subjects at 12 months; 60% were rescue-free up to Month 12.","No drug-related ocular or systemic serious adverse events in OTX-TKI arm; one SAE of endophthalmitis related to injection procedure.","Company plans to initiate a pivotal trial in wet AMD as early as Q3 2023, subject to obtaining necessary financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-070107","json":"https://secwatch.observer/filing/0001104659-23-070107.json","markdown":"https://secwatch.observer/filing/0001104659-23-070107.md","text":"https://secwatch.observer/filing/0001104659-23-070107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923070107/0001104659-23-070107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923070107/tm2318436d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T02:49:29.461475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}